This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Investigations and diagnosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Persistently raised haematocrit M >0·52, F >0·48

Clinical history/examination/1st line investigaions includes EPO

May identify Clear secondary cause - if not then check JAK2 V617F mutational analysis (PB) - if positive then diagnose PV

  • significant, JAK2-unmutated erythrocytosis.
  • consider red cell mass to confirm (if Hct<0·6/0·56)
  • consider USS abdomen

Is there a likely secondary cause from clinical history, stage 1/2 investigations, USS abdomen

statify by serum erythropoietin

  • if serum erythropoetin is normal or low then JAK2 exon 12 mutation analysis; consider bone marrow biopsy

Stage 1 Investigations


Full blood count/blood film, Renal and liver function, Arterial oxygen saturation (SaO2)/carboxyhaemoglobin, Serum ferritin, Serum erythropoietin, JAK2 V617F mutational analysis

  • Full blood count/blood film
    • full blood count analysis will not only confirm a raised Hct but will also identify neutrophilia and thrombocytosis - are common in JAK2 V617F-positive PV and part of
      the criteria for JAK2-negative PV
      • smokers have a significantly higher neutrophil count than non-smokers - neutrophilia is defined as>12.5x 10^9/l in this patient group

  • blood film
    • if confirmed PV, abnormalities, such as circulating blasts, leucoerythroblastic features and monocytosis, would be indications for bone marrow assessment

  • renal, liver function, bone profile
    • various renal and hepatic diseases can cause erythrocytosis
    • serum calcium levels should also be determined to exclude a parathyroid adenoma/carcinoma - rare causes of secondary erythrocytosis

Erythropoetin

  • high EPO levels
    • may occur in hypoxic conditions or when erythrocytosis is secondary to exogenous administration or endogenous overproduction
  • EPO levels are typically low in PV

Serum ferritin

  • low serum ferritin levels are common in PV patients and iron deficiency can mask the presentation of PV > giving a misleadingly low Hct because iron deficiency limits erythropoiesis and hypochromic microcytosis develops.

JAK2 V617F mutational analysis

  • identification of JAK2 mutations in almost all PV patients has revolutionised the diagnosis of PV. The JAK2 V617F mutation can be found in over 95% of PV patients and an exon 12 mutation in most remaining patients
    • testing for JAK2 V617F in peripheral blood is sensitive and bone marrow samples are not required to identify this
    • testing for JAK2 V617F is advised as a stage 1 investigation and should confirm the diagnosis the vast majority of PV patients.

2) Further investigations in JAK2 V617F-negative erythrocytosis

Further investigations are warranted in those patients with a persistent, significant erythrocytosis if JAK2 V617F studies are negative and a secondary cause is not immediately apparent. Secondary causes must be considered because PV is rare in the absence of a JAK2 V617F mutation

Red cell mass studies

  • patients with Hct >0.60 (males) or >0.56 (females) can be assumed to have an absolute erythrocytosis, but in others RCM studies can be helpful to confirm an absolute erythrocytosis
  • an RCM more than 25% above the mean predicted value is diagnostic of an absolute erythrocytosis

Those with a raised Hct but an RCM within the normal range have an apparent erythrocytosis.

  • a relative erythrocytosis, found in states of dehydration, can be confirmed when the RCM is within the normal range and plasma volume is below normal
  • patients with a relative or apparent erythrocytosis require no further investigation

Abdominal ultrasound

  • radiological splenomegaly is a minor criterion for JAK2 V617F-negative PV and ultrasound is the simplest method for detection
  • can also exclude secondary causes of erythrocytosis, particularly renal and hepatic pathology, including hepatocellular carcinoma

Further testing can be stratified according to the EPO level measured during stage 1 investigations

Normal or low EPO level

JAK2 exon 12 analysis

  • compared with JAK2 V617F, patients with exon 12 mutated- PV tend to be
    • younger,
    • with higher haemoglobin concentrations,
    • lower white blood cell (WBC) and platelet counts, and
    • an isolated increase in erythropoiesis without granulocytic or megakaryocytic morphological abnormalities

In contrast to JAK2 V617F testing, a discrepancy between exon 12 mutant allele burden in bone marrow and peripheral blood has occasionally been described.

High EPO level

A raised EPO level should lead to a thorough search for secondary causes of erythrocytosis, which may require additional supplementary investigations.

  • CT head and neck
    -Cerebellar haemangioblastoma
    -Meningioma
    -Parathyroid carcinoma/adenoma

  • consider further investigaion for secondary cause if clinically suspected
    -referral to respiratory/renal, sleep studies

Reference:

McMullin MF et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005 Jul;130(2):174-95

McMullin MF et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.British Journal of Haematology, 2019, 184, 176-191


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.